UK biotech N4 Pharma, a company developing a gene delivery system to enable advanced therapies for cancer and other diseases, has appointed David Solomon as Chief Executive Officer (CEO).
David brings over 30 years of international leadership experience in biotechnology, pharmaceuticals and healthcare innovation to the role. His past roles include serving as the CEO of Zealand Pharma, leading the company through its Nasdaq Copenhagen IPO and the global approval of its lead product, Lixisenatide, a GLP-1 receptor agonist for type 2 diabetes marketed by Sanofi.
David previously worked on licensing agreements with Sanofi, Boehringer Ingelheim, Lilly, AbbVie and Helsinn. He has also served on a number of biotech company boards, including as Chairman and Director for companies such as Advicenne and Rexgenero, and was a founder of Carrot Capital Healthcare Ventures.
The appointment builds on N4 Pharma’s planned transition to a therapeutic biotechnology company focused on developing innovative RNA-based therapeutics.
The company is to be renamed Thalia Therapeutics to reflect its strategic transition.
Chris Britten, Non-Executive Chairman of N4 Pharma, said: “David’s considerable experience in leading listed biotechnology businesses in Europe and the US, his knowledge of RNA therapeutics, combined with his strategic and commercial insight, deal-making and corporate finance successes, makes him ideally suited to lead the company through its next phase of development as Thalia Therapeutics.
David Solomon, CEO, added: “The planned transition to Thalia Therapeutics reflects a clear strategy, underpinned by new programmes addressing large, high-growth markets and our differentiated RNA delivery platform. “
Company founder, Nigel Theobald, has announced his retirement and stepped down as CEO and a director of the company.